Login to Your Account

Clinic Roundup

Thursday, January 6, 2011
• Opexa Therapeutics Inc., of The Woodlands, Texas, said it completed FDA meetings to review its optimized manufacturing process for multiple sclerosis vaccine Tovaxin and to discuss a pivotal Phase III trial plan. The drug failed its Phase IIb trial, but a subgroup of patients who were treatment-naïve except for steroids demonstrated a significantly reduced annualized relapse rate and will form the basis for the Phase III study. Opexa's shares (NASDAQ:OPXA) jumped 84cents, or 54 percent, to close at $2.40 on Wednesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription